Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Total 13F shares
-
13,022,042
-
Share change
-
-276,306
-
Total reported value
-
$115,449,037
-
Put/Call ratio
-
0.29%
-
Price per share
-
$8.87
-
Number of holders
-
63
-
Value change
-
-$2,396,478
-
Number of buys
-
21
-
Number of sells
-
21
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q4 2022
As of 31 Dec 2022,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
63 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,022,042 shares.
The largest 10 holders included
MENORA MIVTACHIM HOLDINGS LTD., Stonepine Capital Management, LLC, CREDIT SUISSE AG/, Harel Insurance Investments & Financial Services Ltd., RTW INVESTMENTS, LP, Migdal Insurance & Financial Holdings Ltd., GREAT POINT PARTNERS LLC, Wildcat Capital Management, LLC, Clal Insurance Enterprises Holdings Ltd, and Opaleye Management Inc..
This page lists
63
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.